Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m
pharmafile | December 1, 2020 | News story | Manufacturing and Production, Sales and Marketing | AstraZeneca, Crestor, Grunenthal
Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth a possible $350 million.
The deal awards Grünenthal the rights to market the Crestor in more than 30 European countries in Europe; however, the UK and Spain are excluded from the deal. In the same countries covered under the agreement, the drug generated sales of $136 million with a profit before tax of $98 million in 2019.
Upon closing of the deal expected in the first quarter of next year, Grünenthal will make an upfront payment of $320 million to AZ, with further milestone payments of up to $30 million to potentially follow.
“This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients,” commented Ruud Dobber, Executive Vice President at AZ’s BioPharmaceuticals Business Unit. Grünenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe.”
AZ confirmed that it will retain the rights to the medicine in the US, Japan, China and others not covered in the deal, and will continue to handle manufacturing to supply Grünenthal with the drug during the transition period.
Matt Fellows
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …